{
    "hands_on_practices": [
        {
            "introduction": "Effective delirium prevention requires more than just a checklist of interventions; it demands strategic prioritization, especially in urgent clinical situations. For a high-risk patient, clinicians must decide where to focus their limited time and resources for maximum impact. This practice  introduces a quantitative framework for decision-making, challenging you to rank preventive actions by calculating their expected risk reduction based on both clinical evidence and practical feasibility. Mastering this approach transforms clinical intuition into a data-driven strategy for patient care.",
            "id": "5174002",
            "problem": "A $78$-year-old man scheduled for urgent fixation of a hip fracture is classified as American Society of Anesthesiologists (ASA) Physical Status class $IV$ for severe systemic disease (heart failure with reduced ejection fraction and chronic kidney disease). He takes multiple medications including oxybutynin and diphenhydramine, has moderate hearing loss without his hearing aids, and has impaired vision from cataracts. He is cognitively intact at baseline. The team’s aim is to minimize postoperative delirium, defined as an acute, fluctuating disturbance in attention and cognition after surgery, by selecting and sequencing a set of feasible perioperative interventions.\n\nUse the following fundamental bases to guide your reasoning:\n- Postoperative delirium risk increases with anticholinergic burden (consistent with the cholinergic deficiency hypothesis), sensory deprivation, deep anesthesia, sleep disruption, uncontrolled pain, hypoxia, and immobility. Multicomponent nonpharmacologic bundles mitigate several of these drivers simultaneously.\n- Relative risk (RR) is the ratio of event probability under an intervention to the event probability without the intervention. Expected value reasoning dictates prioritizing actions that maximize expected absolute risk reduction, adjusted by feasibility (probability that the action can be successfully implemented in the given setting).\n\nAssume the baseline probability of postoperative delirium in this patient population without targeted mitigation is $p_0 = 0.45$. From high-quality studies applicable to this context, you may take the following well-tested approximate effects and feasibility estimates for single interventions applied independently in this setting:\n- Medication reconciliation and targeted deprescribing to remove anticholinergics and avoid perioperative benzodiazepines: $RR = 0.60$; feasibility $f = 0.90$.\n- Sensory enhancement and orientation measures (portable hearing amplifiers at bedside, ensuring eyeglasses or temporary visual aids, orientation board, family call schedule): $RR = 0.70$; $f = 0.95$.\n- Multicomponent nonpharmacologic delirium-prevention bundle (sleep hygiene, early mobilization, reorientation, hydration, constipation prevention, daytime light exposure): $RR = 0.75$; $f = 0.70$ given staffing constraints.\n- Intraoperative depth-of-anesthesia monitoring to avoid unnecessarily deep anesthesia while maintaining adequate hypnosis and analgesia: $RR = 0.85$; $f = 1.00$.\n- Regional analgesia (fascia iliaca block) with multimodal opioid-sparing analgesia: $RR = 0.80$; $f = 0.85$.\n\nAssume independence of effects for the purpose of ranking single-action expected impacts, and that feasibility $f$ reflects the probability of full, protocol-concordant implementation for each intervention. Your goal is to prioritize the sequence of interventions for this patient by ordering them from first to last to maximize expected reduction in delirium cases per $100$ similar patients, while also considering time-to-implement in the urgent preoperative window and the plausibility of reliably delivering the intervention in this institution.\n\nWhich sequence most appropriately prioritizes risk mitigation actions based on expected impact and feasibility in this setting?\n\nA. Deprescribe anticholinergics and avoid benzodiazepines → Sensory enhancement and orientation → Multicomponent bundle → Regional analgesia with multimodal regimen → Depth-of-anesthesia monitoring\n\nB. Depth-of-anesthesia monitoring → Regional analgesia with multimodal regimen → Multicomponent bundle → Sensory enhancement and orientation → Deprescribe anticholinergics and avoid benzodiazepines\n\nC. Sensory enhancement and orientation → Multicomponent bundle → Depth-of-anesthesia monitoring → Regional analgesia with multimodal regimen → Deprescribe anticholinergics and avoid benzodiazepines\n\nD. Multicomponent bundle → Sensory enhancement and orientation → Deprescribe anticholinergics and avoid benzodiazepines → Depth-of-anesthesia monitoring → Regional analgesia with multimodal regimen",
            "solution": "The goal is to prioritize interventions based on the expected absolute risk reduction, which accounts for both the effectiveness of the intervention (relative risk, RR) and the likelihood of its successful implementation (feasibility, $f$). The expected absolute risk reduction (EARR) for a single intervention can be calculated using the formula: EARR $= p_0 \\times (1 - RR) \\times f$, where $p_0$ is the baseline risk. We will calculate this for each intervention per 100 patients. Given $p_0 = 0.45$.\n\n- **Deprescribe anticholinergics and avoid benzodiazepines**:\n  EARR = $0.45 \\times (1 - 0.60) \\times 0.90 = 0.162$.\n  Expected cases prevented per 100 patients = $16.2$.\n\n- **Sensory enhancement and orientation**:\n  EARR = $0.45 \\times (1 - 0.70) \\times 0.95 = 0.12825$.\n  Expected cases prevented per 100 patients = $12.8$.\n\n- **Multicomponent bundle**:\n  EARR = $0.45 \\times (1 - 0.75) \\times 0.70 = 0.07875$.\n  Expected cases prevented per 100 patients = $7.9$.\n\n- **Regional analgesia with multimodal regimen**:\n  EARR = $0.45 \\times (1 - 0.80) \\times 0.85 = 0.0765$.\n  Expected cases prevented per 100 patients = $7.7$.\n\n- **Depth-of-anesthesia monitoring**:\n  EARR = $0.45 \\times (1 - 0.85) \\times 1.00 = 0.0675$.\n  Expected cases prevented per 100 patients = $6.8$.\n\nRanking the interventions from highest to lowest expected impact yields the following order:\n1.  Deprescribe anticholinergics and avoid benzodiazepines (16.2 cases prevented)\n2.  Sensory enhancement and orientation (12.8 cases prevented)\n3.  Multicomponent bundle (7.9 cases prevented)\n4.  Regional analgesia with multimodal regimen (7.7 cases prevented)\n5.  Depth-of-anesthesia monitoring (6.8 cases prevented)\n\nThis ranking also aligns with clinical practicality in an urgent setting. Deprescribing and arranging sensory aids can be done quickly preoperatively and have a large impact. The multicomponent bundle and regional analgesia are initiated peri- and postoperatively. Depth monitoring has the smallest, though still valuable, incremental impact.\n\n- Option A presents the interventions in this exact order of priority.\n- Options B, C, and D present different, suboptimal orderings that do not prioritize the interventions with the highest expected impact first.\n\nTherefore, the sequence in option A represents the most rational, data-driven prioritization strategy.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Among the most powerful tools for delirium prevention is the careful management of a patient's medication list to reduce cumulative anticholinergic effects, a direct application of the cholinergic deficiency hypothesis of delirium. This exercise  moves from theory to practice, tasking you with a detailed medication review for a complex postoperative patient. By calculating the Anticholinergic Cognitive Burden (ACB) score and navigating multiple clinical constraints to choose safer alternatives, you will hone the essential skill of targeted, evidence-based deprescribing.",
            "id": "5173972",
            "problem": "A patient on a systemic surgery service is on postoperative day $1$ after open abdominal surgery. Prevention and management of postoperative delirium is a priority. A well-tested clinical observation is that pharmacological antimuscarinic effects impair central cholinergic transmission, which worsens attention and increases the likelihood of delirium. The Anticholinergic Cognitive Burden (ACB) instrument classifies individual medications into ordinal categories $1$, $2$, or $3$ that reflect increasing anticholinergic cognitive burden; tools based on expert consensus and pharmacologic profiling apply these categories to estimate regimen burden. The patient’s current inpatient medication list (indication in parentheses) with ACB categories is:\n\n- Diphenhydramine $25$ mg nightly (insomnia): ACB $3$.\n- Oxybutynin extended-release $10$ mg daily (overactive bladder): ACB $3$.\n- Amitriptyline $25$ mg nightly (neuropathic pain): ACB $3$.\n- Cyclobenzaprine $5$ mg three times daily as needed (muscle spasm): ACB $2$.\n- Paroxetine $20$ mg daily (major depressive disorder): ACB $3$.\n- Promethazine $25$ mg as needed (nausea): ACB $3$.\n- Chlorpheniramine $4$ mg twice daily (allergic rhinitis): ACB $3$.\n\nTo preserve therapeutic intent for each indication while minimizing delirium risk, the team considers substitutions. The following substitution options are available, with their ACB categories and clinical constraints derived from the patient’s current status: blood pressure $182/112$ mmHg, corrected QT interval $470$ ms, estimated glomerular filtration rate $35 \\text{ mL/min/1.73 m}^2$, alanine aminotransferase $5 \\times$ upper limit of normal, history of seizure disorder, and prior postoperative delirium precipitated by gabapentin.\n\n- Insomnia: melatonin (ACB $0$) is permitted; trazodone (ACB $1$) is permitted.\n- Overactive bladder: mirabegron (ACB $0$) is contraindicated because of severe uncontrolled hypertension; no other non-anticholinergic alternatives are available; one antimuscarinic must be continued.\n- Neuropathic pain: duloxetine (ACB $0$) is contraindicated due to hepatic enzyme elevation; gabapentin (ACB $0$) is contraindicated due to prior delirium; pregabalin (ACB $0$) is unavailable; nortriptyline (ACB $3$) is the only tolerated effective option.\n- Muscle spasm: baclofen (ACB $0$) is permitted; tizanidine (ACB $0$) is contraindicated due to hypotension risk in this patient.\n- Major depressive disorder: sertraline (ACB $0$) is permitted; escitalopram (ACB $0$) is contraindicated due to prolonged $QT$; bupropion (ACB $0$) is contraindicated due to seizure disorder.\n- Nausea: ondansetron (ACB $0$) is contraindicated due to prolonged $QT$; metoclopramide (ACB $0$) is permitted.\n- Allergic rhinitis: cetirizine (ACB $0$) and loratadine (ACB $0$) are permitted.\n\nAssume that for each indication, exactly one agent must be selected to preserve therapeutic intent, selected from the current agent or one of the permitted substitutions for that indication. Under these constraints, and using the widely accepted practice that the regimen’s anticholinergic cognitive burden is assessed by aggregating the categorical contributions of the active agents, determine the minimal attainable total burden for this patient’s regimen. Express your final answer as an integer without units. No rounding is required.",
            "solution": "The goal is to minimize the total Anticholinergic Cognitive Burden (ACB) by selecting the medication with the lowest possible ACB score for each of the seven indications, while adhering to all clinical constraints. The total ACB is the sum of the scores from the selected medications.\n\n1.  **Insomnia**: The current medication is Diphenhydramine (ACB 3). To minimize the burden, substitute with the permitted option having the lowest score, which is Melatonin (ACB 0). Minimal ACB = **0**.\n\n2.  **Overactive bladder**: The current medication is Oxybutynin (ACB 3). The non-anticholinergic option (Mirabegron, ACB 0) is contraindicated. A crucial constraint states, \"one antimuscarinic must be continued.\" As Oxybutynin is the only available antimuscarinic for this indication, it must be continued. Minimal ACB = **3**.\n\n3.  **Neuropathic pain**: The current medication is Amitriptyline (ACB 3). All low-ACB alternatives are contraindicated or unavailable. The only remaining effective option is Nortriptyline (ACB 3). The burden cannot be reduced. Minimal ACB = **3**.\n\n4.  **Muscle spasm**: The current medication is Cyclobenzaprine (ACB 2). Substitute with the permitted low-burden alternative, Baclofen (ACB 0). Minimal ACB = **0**.\n\n5.  **Major depressive disorder**: The current medication is Paroxetine (ACB 3). Substitute with the permitted low-burden alternative, Sertraline (ACB 0). Minimal ACB = **0**.\n\n6.  **Nausea**: The current medication is Promethazine (ACB 3). Substitute with the permitted low-burden alternative, Metoclopramide (ACB 0). Minimal ACB = **0**.\n\n7.  **Allergic rhinitis**: The current medication is Chlorpheniramine (ACB 3). Substitute with a permitted low-burden alternative like Cetirizine or Loratadine (both ACB 0). Minimal ACB = **0**.\n\nThe minimal attainable total ACB score is the sum of these individual minimums:\nTotal ACB = 0 (Insomnia) + 3 (Bladder) + 3 (Pain) + 0 (Spasm) + 0 (Depression) + 0 (Nausea) + 0 (Rhinitis) = **6**.",
            "answer": "$$\\boxed{6}$$"
        },
        {
            "introduction": "Not all postoperative delirium is the same, and misdiagnosis can lead to significant harm by prompting inappropriate treatment. This final practice presents a challenging case  designed to test your diagnostic acumen in distinguishing typical postoperative delirium from the life-threatening syndrome of delirium tremens due to alcohol withdrawal. Successfully navigating this scenario requires applying first principles of neuropharmacology to justify a specific treatment pathway, reinforcing why benzodiazepines—typically avoided in delirium management—become an essential, first-line therapy in this critical exception.",
            "id": "5174052",
            "problem": "A $62$-year-old man with a history of hypertension and daily alcohol intake of approximately $8$ standard drinks presents for an elective laparoscopic sigmoid colectomy. On postoperative day $2$, he becomes acutely confused, disoriented to place and time, and intermittently combative. Vital signs show heart rate $122\\,\\mathrm{beats/min}$, blood pressure $164/92\\,\\mathrm{mmHg}$, temperature $37.7\\,^\\circ\\mathrm{C}$, and oxygen saturation $96\\%$ on room air. He reports visual hallucinations of “insects on the wall,” has coarse tremor, diaphoresis, and psychomotor agitation. Nursing notes indicate that his last alcoholic drink was approximately $36$ hours before admission. Laboratory evaluation reveals aspartate aminotransferase (AST) $146\\,\\mathrm{U/L}$, alanine aminotransferase (ALT) $58\\,\\mathrm{U/L}$, total bilirubin $2.4\\,\\mathrm{mg/dL}$, and normal serum creatinine. The Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) score is $18$, with a score distribution notable for tremor $6$, agitation $5$, hallucinations $4$, and anxiety $3$. His Richmond Agitation-Sedation Scale (RASS) is $+2$.\n\nYou are asked to design a protocol that aligns with prevention and management principles for postoperative delirium in systemic surgery. The protocol must be justified from first principles of neuropharmacology and validated assessment tools, making explicit why benzodiazepines are generally avoided in postoperative delirium but are indicated for alcohol withdrawal. The protocol should incorporate: (i) parenteral thiamine administration before any glucose-containing solutions, (ii) symptom-triggered benzodiazepine dosing guided by CIWA-Ar thresholds, and (iii) an adjunctive phenobarbital strategy for benzodiazepine-refractory cases, with safety monitoring. Consider hepatic function when selecting agents.\n\nWhich of the following protocols is most appropriate?\n\nA. Initiate haloperidol $2\\,\\mathrm{mg}$ intravenous every $6$ hours for delirium control, avoid benzodiazepines entirely because they worsen delirium, begin $5\\%$ dextrose infusion immediately for nutrition, and reassess CIWA-Ar only once daily. Do not give thiamine because the patient is eating. Avoid phenobarbital due to risk of respiratory depression.\n\nB. Administer intravenous thiamine $100\\,\\mathrm{mg}$ before any glucose-containing fluids; employ a symptom-triggered benzodiazepine regimen guided by CIWA-Ar: for CIWA-Ar $\\geq 8$–$10$, give lorazepam $1$–$2\\,\\mathrm{mg}$ intravenous, repeat every $10$–$15$ minutes until the patient is calm but arousable, and reassess CIWA-Ar hourly; for CIWA-Ar $\\geq 15$ or persistent agitation despite cumulative lorazepam $6$–$8\\,\\mathrm{mg}$, add phenobarbital $130$–$260\\,\\mathrm{mg}$ intravenous as adjunct, with continuous cardiorespiratory monitoring and airway readiness; otherwise avoid benzodiazepines for non–alcohol-withdrawal delirium and prioritize nonpharmacologic measures with antipsychotics only if severe agitation threatens safety.\n\nC. Begin fixed-schedule diazepam $10\\,\\mathrm{mg}$ intravenous every $6$ hours regardless of CIWA-Ar, provide $500\\,\\mathrm{mL}$ of $10\\%$ dextrose before thiamine to correct hypoglycemia faster, and administer phenobarbital $260\\,\\mathrm{mg}$ intravenous upfront to all agitated postoperative patients to prevent progression to delirium tremens. Reassess CIWA-Ar every $8$ hours.\n\nD. Treat postoperative delirium with lorazepam $2\\,\\mathrm{mg}$ intravenous every $4$ hours to ensure sleep restoration in all cases because benzodiazepines are broad-spectrum anxiolytics; CIWA-Ar is not necessary postoperatively. If agitation persists, increase lorazepam to $4\\,\\mathrm{mg}$ intravenous every $2$ hours. Administer thiamine after stabilization and start glucose immediately to prevent catabolism. Avoid phenobarbital due to drug interactions.\n\nE. Start dexmedetomidine infusion at $0.2$–$0.7\\,\\mathrm{\\mu g/kg/h}$ to prevent and treat delirium while avoiding benzodiazepines entirely; do not obtain CIWA-Ar because continuous sedation controls symptoms; phenobarbital is unnecessary; thiamine can be given after glucose since the infusion dose is small.",
            "solution": "The patient's clinical presentation is a classic case of severe alcohol withdrawal syndrome (AWS), specifically delirium tremens (DTs), not typical postoperative delirium. The management must target the underlying pathophysiology of AWS. The core neuropharmacological principle is that chronic alcohol use causes central nervous system adaptation (enhanced GABAergic inhibition). Abrupt withdrawal leads to a dangerous hyperexcitable state from GABA deficiency.\n\nKey principles for managing severe AWS are:\n-   **Benzodiazepines (BZDs)** are the first-line, mechanism-based treatment. They augment GABAergic neurotransmission, directly counteracting the withdrawal state. This is a critical exception to the general rule of avoiding BZDs in delirium.\n-   **Thiamine** must be administered parenterally *before* any glucose-containing solutions to prevent Wernicke's encephalopathy, a neurological emergency.\n-   **Symptom-triggered therapy**, guided by a validated scale like the CIWA-Ar, is the standard of care.\n-   **Choice of BZD**: Given evidence of liver dysfunction (elevated liver enzymes), a BZD that bypasses oxidative hepatic metabolism, such as **lorazepam**, is preferred.\n-   **Refractory DTs**: For patients who remain agitated despite high BZD doses, an adjunctive agent like **phenobarbital** is indicated, which requires intensive cardiorespiratory monitoring.\n\nEvaluating the options:\n-   **A**: Incorrect. Fails to treat AWS, inappropriately uses haloperidol monotherapy, and dangerously orders glucose before thiamine.\n-   **B**: **Correct**. This protocol follows all evidence-based guidelines: thiamine before glucose, symptom-triggered lorazepam (a safe choice for this patient), frequent CIWA-Ar monitoring, and a rational plan for refractory treatment with phenobarbital, including necessary safety precautions. It also correctly contextualizes BZD use.\n-   **C**: Incorrect. Uses a suboptimal fixed-schedule regimen, a less safe BZD (diazepam) in liver disease, and orders glucose before thiamine.\n-   **D**: Incorrect. Falsely advocates BZDs for all delirium, dismisses the essential CIWA-Ar scale, and reverses the thiamine/glucose order.\n-   **E**: Incorrect. Inappropriately suggests dexmedetomidine as a replacement for BZDs. Dexmedetomidine does not treat the underlying pathophysiology or prevent seizures and is only an adjunct.\n\nTherefore, protocol B is the only one that is safe, effective, and evidence-based for this patient's condition.",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}